Trial · NCT02048813
Adverse events372
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 372
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm A (Ibrutinib, Rituximab) | 183 | 352 | |
| other | Anemia | Blood and lymphatic system disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 99 | 158 | |
| other | Atrial fibrillation | Cardiac disorders | Arm A (Ibrutinib, Rituximab) | 27 | 352 | |
| other | Atrial fibrillation | Cardiac disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 0 | 158 | |
| other | Palpitations | Cardiac disorders | Arm A (Ibrutinib, Rituximab) | 30 | 352 | |
| other | Palpitations | Cardiac disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 1 | 158 | |
| other | Chills | General disorders | Arm A (Ibrutinib, Rituximab) | 20 | 352 | |
| other | Chills | General disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 17 | 158 | |
| other | Edema limbs | General disorders | Arm A (Ibrutinib, Rituximab) | 61 | 352 | |
| other | Edema limbs | General disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 14 | 158 | |
| other | Fatigue | General disorders | Arm A (Ibrutinib, Rituximab) | 235 | 352 | |
| other | Fatigue | General disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 105 | 158 | |
| other | Fever | General disorders | Arm A (Ibrutinib, Rituximab) | 42 | 352 | |
| other | Fever | General disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 32 | 158 | |
| other | Infusion related reaction | General disorders | Arm A (Ibrutinib, Rituximab) | 28 | 352 | |
| other | Infusion related reaction | General disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 39 | 158 | |
| other | Pain | General disorders | Arm A (Ibrutinib, Rituximab) | 22 | 352 | |
| other | Pain | General disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 3 | 158 | |
| other | General disorders and administration site conditions - Other | General disorders | Arm A (Ibrutinib, Rituximab) | 26 | 352 | |
| other | General disorders and administration site conditions - Other | General disorders | Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide) | 1 | 158 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02048813/events